Wednesday, October 1, 2014

STEMEDICA SECURES U.S. PATENT TO USE MULTIPLE STEM CELL LINES SIMULTANEOUSLY TO TREAT ISCHEMIC STROKE

(Source: October 1; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, was issued a new patent from the U.S. Patent & Trademark Office (USPTO), US 8,790,638 entitled “Composition of Stem Cells and Stem Cell Factors for Their Use and Manufacture.” This patent covers a method for treating patients with ischemic stroke, and the treatment includes intrathecal administration of hypoxically grown neural stem cells and intravenous administration of hypoxically grown mesenchymal stem cells.
“The issuance of this patent by the USPTO confirms a novel approach in the world of stem cell medicine – the simultaneous use of multiple stem cell lines to treat diseases,” says Stemedica’s President and Chief Medical Officer Nikolai Tankovich, M.D., Ph.D., FASLMS. “This combinatory approach targets various damaged tissues synergistically and uses different repair mechanisms that include, but are not limited to, treating a brain stroke from both sides of the blood-brain barrier. We believe that intravenous administration of Stemedica’s ischemia-tolerant mesenchymal stem cells (itMSCs) will help to release hundreds of repair proteins – the paracrine function of stem cells – to restore and build new vascularization and to improve the blood supply in tissues affected by stroke. Concurrently, via intrathecal administration, Stemedica’s ischemia-tolerant neural stem cells (itNSCs) will migrate to and replace damaged neurons, engraft into the brain’s neural network and produce neuromediators and electrical pulses to reconnect the damaged neural network and improve functionality of areas affected by the stroke.
“This patent presents a tremendous opportunity for Stemedica to introduce a new, combination method to treat patients suffering from the effects of ischemic stroke and to ameliorate their conditions,” says Stemedica’s Vice President of Intellectual Property Harris Brotman, J.D., Ph.D. “We hope our patented treatment methodology will alleviate the after-effects of ischemic strokes.”
Invented by Stemedica’s Chief Technology Officer Alex Kharazi, M.D., Ph.D., and Dr. Nikolai Tankovich, the new patent covers the treatment of stroke with two types of hypoxically grown stem cells, each with a different administration method. Stemedica’s itMSCs and itNSCs have obtained cGMP certification. itMSCs are currently being used in FDA-approved, Phase II clinical trials in the United States and internationally, and itNSCs are ready for clinical use beginning with Phase I-IIa safety studies.
Licensed by California’s Food and Drug Branch, Stemedica produces multiple adult, allogeneic stem cell lines grown under low-oxygen conditions (US Patent 8,420,394 entitled “Culturing Ectodermal Cells Under Reduced Oxygen Tension”), which is their natural environment in the body. Compared with cells grown under normoxic, or standard-oxygen conditions, in vitro experiments demonstrate that hypoxically grown cells show greater homing and engraftment, and they secrete higher levels of growth factors and other important proteins associated with neoangiogenesis and healing.
About Stemedica Cell Technologies Inc. 
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that manufactures best-in-class, allogeneic, adult stem cells and stem cell-derived factors. The company is a government-licensed manufacturer of cGMP, clinical-grade stem cells currently used in clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. Stemedica’s products are also used by research institutions and hospitals for pre-clinical and clinical (human) trials. Under the auspices of the FDA and other international regulatory institutions, Stemedica is developing clinical trials for other indications using its adult, allogeneic stem cells. The company has headquarters in San Diego, California, and can be found online at www.stemedica.com. .
All media inquiries:
Kimberly Stoddard
The Townsend Team
415.806.5793
kimberly@townsendteam.com

Monday, June 9, 2014

STEMEDICA EARNS U.S. PATENT FOR CELLULAR SCAFFOLD ENHANCED BY STEM CELL FACTORS

(Source: June 9; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, received a new patent from the U.S. Patent & Trademark Office, US8709081 entitled “Cellular Scaffold.” This patent, coupled with the US8105380 patent issued in 2012, extends Stemedica’s proprietary technology to therapeutic skin regeneration. The scaffolds are human skin equivalents that can be transplanted to regenerate skin in patients with skin defects, such as burn injuries, or diseases affecting skin, such as diabetic ulcers.
“Adding biologically active factors to Stemedica’s original, patented cellular scaffolds might increase the engrafting capability and the potency of engrafted cells,” says Alex Kharazi, M.D., Ph.D., Chief Technology Officer of Stemedica. “We expect our newly patented technology to enhance the overall performance of the scaffold and make it more competitive among available, human skin equivalents.”
Invented by Dr. Alex Kharazi, Dr. Ludmila Kharazi, Stemedica’s Senior Research Scientist, and Dr. Nikolai Tankovich, Stemedica’s President and Chief Medical Officer, the new patent contains stem cell factors derived from the cells to enhance cellular effect and modulate stem cell action. The cellular scaffolds are used in cell-based assays, and they detect in vitro effects of environmental factors and chemical factors on skin development. The invention relates to a layered cell scaffold that is seeded with mesenchymal and ectodermal cells, as well as molecules (collectively called stem cell factors) derived from those cells. The layered cellular scaffold comprises an inoculum of mesenchymal cells and ectodermal cells positioned between two opposing scaffolds in a sandwich configuration.
“Our newest patent is a significant achievement in tissue engineering, and it is another example of how Stemedica applies its expertise to push the boundary of what is possible with stem cells,” says Nikolai Tankovich, M.D., Ph.D., FASLMS, President, Chief Medical Officer and Director of Stemedica. “Stemedica is designing truly regenerative medicine – treatments that address core problems rather than only alleviating symptoms. Our patented scaffolds are designed as multi-layer, multi-cell and multi-compound structures, which more closely resembles how real skin is structured. As a result the scaffolds respond more like human skin than anything we have yet seen. This presents tremendous opportunities for us to treat a significant number of skin pathologies and conditions.”
About Stemedica Cell Technologies Inc. 
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that manufactures best-in-class, allogeneic, adult stem cells and stem cell-derived factors. The company is a government-licensed manufacturer of cGMP, clinical-grade stem cells currently used in clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. Stemedica’s products are also used by research institutions and hospitals for pre-clinical and clinical (human) trial activities. Under the auspices of the FDA and other international regulatory institutions, Stemedica is developing additional clinical trials using its adult, allogeneic stem cells for other medical indications. The company has headquarters in San Diego, California, and can be found online at www.stemedica.com. .
All media inquiries:
Christina Gramatikova
The Townsend Team
858.880.4538
christina@townsendteam.com

Tuesday, May 27, 2014

INDONESIA’S BPOM GRANTS IND APPROVAL FOR SCI TO CONDUCT A PHASE II CLINICAL TRIAL USING STEMEDICA’S MESENCHYMAL STEM CELLS TO TREAT ACUTE MYOCARDIAL INFARCTION

(Source: May 27; San Diego)

Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, announces that its research partner The Stem Cell and Cancer Institute (SCI), a subsidiary of PT Kalbe Farma Tbk, Indonesia, received an IND approval in April 2014 from the Badan Pengawas Obat dan Makanan (BPOM, or the Indonesian FDA) for a Phase II study using Stemedica’s mesenchymal stem cells to treat acute myocardial infarction (AMI) in human subjects in Indonesia. The IND was filed by SCI with support from Stemedica Asia, a subsidiary of Stemedica, and was based on Stemedica’s United States FDA-approved Phase II AMI trial protocol.
“Stemedica’s management team is exceptionally pleased that SCI has received this IND approval. Until now, no allogeneic stem cell trial had been approved in Southeast Asia,” says Dr. Nikolai Tankovich, Chief Medical Officer and President of Stemedica and Chairman of Stemedica Asia Pte. Ltd.
Dr. Tankovich particularly is grateful that Kalbe has tirelessly been working to bring the highest standard and quality assurance to its stem cell biologics development effort. The Biopharma Division of the Kalbe Group, comprising of the Stem Cell and Cancer Institute, Innogene Kalbiotech and PharmaMetric Labs, vigorously prepared and provided all the necessary documents and answers to the BPOM and established that it can safely conduct human trials using allogeneic stem cells in Indonesia.
Placing safety at the top was common ground for both Kalbe and Stemedica. Dr. Tankovich agrees with the Director of the Biopharma Division, Mr. Krish Krishnan who says, “For us, this IND approval from BPOM is validation from the highest authority in Indonesia that Kalbe and Stemedica place patient safety first, and focus on the advancement of medicine based on scientific proof and reproducible trial outcomes.”
The Biopharma Division of Kalbe is also working to file for a provisional IND for chronic heart failure using Stemedica’s mesenchymal stem cells, working closely with CardioCell LLC, a subsidiary of Stemedica devoted to treatment development and commercialization for cardiology.
In addition, Kalbe is reviewing the possibilities of filing the same IND for multisite Phase II trials in several other Southeast Asian countries, thus continuously building a reputation for rigorous regulatory compliance for stem cell therapeutics, in order to answer the needs of the ever-growing and aging population in the region. This IND approval from BPOM places Kalbe as leading Southeast Asia in setting an example for the rest of the region, which will bring healthy competition and awareness for regulatory guidelines and policies for stem cell therapeutics.
About Kalbe Group
PT Kalbe Farma Tbk. (“Kalbe”) was established in 1966 and is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions managing a broad and strong portfolio of brands; prescription pharmaceuticals division (Cefspan, Brainact, Broadced, etc), consumer health division comprising over-the-counter drugs (Promag, Mixagrip, Komix, Woods, Fatigon, etc) as well as ready-to-drink and energy drink products (Hydro Coco, Extra Joss, Nitros), nutritionals division (ChilKid, Prenagen, Diabetasol, etc), and distribution division. Kalbe currently has more than 20 subsidiaries and 10 production facilities with international standards, supported by more than 17,000 employees and 6,000 sales and marketing personnel, spread in 68 branches across Indonesia. Since 1991, Kalbe’s shares have been listed on the Indonesia Stock Exchange (IDX: KLBF). www.kalbe.co.id.
About Stemedica Cell Technologies Inc. 
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that manufactures best-in-class, allogeneic, adult stem cells and stem cell-derived factors. Under the auspices of the U.S. FDA and other international regulatory institutions, Stemedica manufactures cGMP, clinical-grade stem cells, which the company currently uses in clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. Stemedica’s products are also used by research institutions and hospitals for pre-clinical and clinical (human) trial activities. Stemedica is currently developing additional clinical trials for other medical indications. The company has headquarters in San Diego, California, USA, and can be found online at www.stemedica.com. .
Stemedica Cell Technologies is a trademark of Stemedica Cell Technologies. Other company and product names are trademarks of their respective owners.
North America inquiries:
Christina Gramatikova
The Townsend Team
858.880.4538
christina@townsendteam.com
Asia inquiries:
Amy Lee
Stemedica Asia Pte. Ltd.
+1 858.249.1279
alee@stemedica.com

Tuesday, April 22, 2014

PRESIDENT OF LEADING SOUTH KOREAN BIOPHARMACEUTICAL COMPANY GREEN CROSS HOLDINGS JOINS STEMEDICA’S BOARD OF DIRECTORS

(Source: April 22; San Diego)

Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes Byung-Geon “BG” Rhee, Ph.D., President of Green Cross Holdings, a South Korean biopharmaceutical company, to its board of directors. Green Cross, whose recent investment closed Stemedica’s Series B funding round, is one of the world’s largest vaccine and plasma product manufacturers, and the company’s influence in Asia, China and the United States spans advanced research and development, biotech manufacturing and product development. Dr. Rhee’s addition to Stemedica’s board supports both companies’ shared vision of moving stem-cell technologies from clinical trials into worldwide medical practice.
“Stemedica is honored to add the President of Green Cross Holdings to our board of directors,” says Roger A. Howe, Ph.D., Executive Chairman of Stemedica. “Dr. Rhee is one of few industry leaders who has a proven track record for bringing innovative new technologies from clinical trials to mainstream medical practice. His expertise will help Stemedica set new standards for stem cell quality and affordability on a global scale.”
BG Rhee
Dr. Byung-Geon Rhee
President Green Cross Holdings
“Green Cross conducted extensive due diligence on stem cell technologies before making the investment to close Stemedica’s funding round,” says Dr. Byung-Geon Rhee, President of Green Cross Holdings. “The more we learned about Stemedica, the more we wanted to participate in its next phase of growth. I am happy to have the opportunity to serve as a member of Stemedica’s board of directors.”
Dr. Rhee has more than 27 years of experience in bio industry. For the past 10 years, he has served in executive-level roles at Green Cross Corp. and now parent company Green Cross Holdings. Before joining the South Korean market leader, he founded United States-based gene-therapy company Expression Genetics, Inc. in 2002. He has also served as Samyang Corp.’s pharmaceutical business unit head and LG Chem’s drug-development division head. He is currently Chairman of Korea Biotechnology Industry Organization (BIO), Co-President for two forums within the South Korea Ministry of Health and Welfare: Health Technology Forum and Infectious Disease R&D Forum. He is member of the National Academy of Engineering of Korea. He earned his B.Sc. and M.Sc. in chemical engineering from Seoul National University, his Ph.D. in chemical/biomedical engineering from Rice University and completed post-doctoral work at the University of Wisconsin, Madison.
About Green Cross
Green Cross is the largest biopharmaceutical company in Korea. Green Cross provides safe and effective healthcare solutions that address the evolving needs of human health. Headquartered in Yongin, South Korea, Green Cross specializes in the development and manufacture of plasma-derivatives, preventive vaccines, recombinant proteins, therapeutic antibodies and cell therapies. The company can be found online at www.greencross.com.
About Stemedica Cell Technologies Inc. 
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class, allogeneic, adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government-licensed manufacturer of clinical-grade stem cells and is approved by the FDA for clinical trials in acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult, allogeneic stem cells. The company has headquarters in San Diego, Calif., and can be found online at www.stemedica.com. .
All media inquiries:
Kimberly Stoddard
The Townsend Team
415.806.5793
kimberly@townsendteam.com

Monday, April 14, 2014

STEMEDICA APPOINTS NIH CENTER FOR REGENERATIVE MEDICINE FORMER FOUNDING DIRECTOR DR. MAHENDRA RAO TO ITS SCIENTIFIC AND MEDICAL ADVISORY BOARD

Renowned Stem Cell and Regenerative Medicine Authority Will Help Stemedica in Its Plans to Meet the Global Demand for Stem Cell Technology

Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes to its Scientific and Medical Advisory Board prominent stem cell and regenerative medicine expert Dr. Mahendra Rao, M.D., Ph.D. As a Founding Director of the National Institute of Health (NIH) Center for Regenerative Medicine (CRM), he has built the Center into a world-class organization recognized for its excellence in the clinical translation of stem cell technology, and his expertise will help Stemedica shape its strategy to meet global demand for its stem cell technology.

“I look forward to a long and beneficial relationship with Stemedica,” Dr. Mahendra Rao says. “In my various professional assignments and industry engagements, I have had an opportunity to extensively review the stem cell technology that is available in the marketplace. I decided to join the Stemedica team because Stemedica has developed an elegant manufacturing process and is committed to cell based therapies for multiple medical diseases that are difficult to treat.”

Dr. Rao is internationally renowned for his research in stem cells and regenerative medicine. He has worked in the stem cell field for more than 20 years, with positions in academia, government, regulatory affairs and industry, and he has authored more than 300 publications. He received his M.D. from Bombay University and his Ph.D. in developmental neurobiology from the California Institute of Technology. Following postdoctoral training at Case Western Reserve University, he established his research laboratory in neural development at the University of Utah. He next joined the National Institute on Aging as Chief of the Neurosciences Section where he studied neural progenitor cells. Most recently, he was Vice President of Regenerative Medicine at Life Technologies.
“We are very fortunate to have someone of Dr. Rao’s caliber join the Stemedica Team,” says Maynard A. Howe, Ph.D., Vice Chairman and CEO of Stemedica. “His experience and expertise are already proving invaluable as Stemedica strengthens its global leadership position in manufacturing multiple stem cell products for use in various clinical trials in the United States and internationally.”
Throughout his career, Dr. Rao has served internationally on advisory boards for companies involved in stem cell processing and translational applications. He has also participated on committees including Chairman of the U.S. Food and Drug Administration’s Cellular Tissue and Gene Therapies Advisory Committee, the California Institute of Regenerative Medicine, International Society for Stem Cell Research and as the liaison to the International Society for Cellular Therapy.
“Based on his extensive stem cell and regenerative medicine accomplishments, Dr. Rao is the ideal candidate to advise Stemedica during this period of rapid growth,” states Alex Kharazi, M.D., Ph.D., CTO of Stemedica Cell Technologies Inc.
About Stemedica Cell Technologies Inc.
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class, allogeneic, adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government-licensed manufacturer of clinical-grade stem cells and is approved by the FDA for clinical trials in acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult, allogeneic stem cells. The company has headquarters in San Diego, Calif., and can be found online at www.stemedica.com 
All media inquiries:
Kimberly Stoddard
The Townsend Team
415.806.5793
kimberly@townsendteam.com

Wednesday, March 26, 2014

STEMEDICA ANNOUNCES INTERNATIONAL EDUCATIONAL COLLABORATION WITH SMART LIVING

(Source: March 26; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc., a specialty biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells and Smart Living, a subsidiary of Smart Global, a $2 billion (USD) globally diversified conglomerate, are pleased to announce an international educational collaboration.
Smart Living currently organizes dynamic “One World” educational conferences designed to introduce breakthrough technologies and educational programs focused on health care and regenerative medicine to countries throughout the world. High profile leaders in medicine, science, business, education, government and community organizers are brought together at these international forums to participate in presentations, discussions and educational programs.
Stemedica, a global leader in regenerative medicine focused on stem cell research and clinical trials, has been selected to introduce breakthrough technologies in the dynamic field of stem cells and their role in translational medicine.
In addition to the educational outreach, Smart Living is making significant advances in health care with its Smart Health City model. This model, anticipated to go global, was developed to be an all-inclusive health care destination offering services including multispecialty hospitals, medical office buildings, medical rehabilitation centers, international patient care centers, medical education and training, clinical research, on campus staff residence, research and technology centers. The first of these Health Cities is on 15 acres located in Saket in the heart of Delhi, India.
Swati Saxena, MD, Programme Director at Smart Living said, “What makes Smart Living a unique concept is that it provides integrated and converged facilities where strong scientific evidence is paired with health and wellness initiatives in a step-by-step methodic fashion guided by medical experts.”
Dr. Bhupendra Kumar (“BK”) Modi, PhD, Chairman Smart Global and Founder of Smart Living said, “We are delighted to make an investment into, and to collaborate with, Stemedica. Our objective is to implement sophisticated technologies, advance new and improved innovations and encourage research for the betterment of the health of society. As Smart Living continues its worldwide educational efforts to promote health and wellbeing, Stemedica’s leadership in the regenerative medicine movement is an ideal fit for our efforts.”
Roger A. Howe, PhD, Stemedica’s Executive Chairman said about the collaboration, “This is an excellent opportunity to contribute to Dr. Modi’s “One World” educational forums. As an active participant in these forums, we will be able to promote healthier lifestyles in communities around the world. Stemedica, together with Smart Living, will emphasize the importance of new innovations that lead to medical breakthroughs in regenerative medicine, including Stemedica’s stem cell technologies.”
As part of the collaboration, Mr. Ozi Amanat, Smart Global Chief Investment Officer will become a business advisor to Stemedica. In accepting the appointment, Mr. Amanat said, “I’m honored to be working with Stemedica and its leadership. Stemedica is poised to bring the power and potential of regenerative medicine to the world. Stemedica’s leadership in this field is exciting and I look forward to supporting their continued growth as well as creating maximum value to both organizations.”
Smart Living has made an undisclosed investment in Stemedica.
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.
For more information regarding Stemedica Cell Technologies, Inc., please contact Dave McGuigan, Vice President of Marketing and Business Development: dmcguigan@stemedica.com
About Smart Global
Smart Global formerly Spice Global, is a $2 billion (USD) diversified conglomerate that encompasses a variety of businesses that harness speed, creativity and efficiency to invest, develop and market products that are defining how we live today. It currently serves over 25 million customers worldwide across various sectors – telecom, finance, entertainment technology and healthcare. Established by renowned global entrepreneur and futurepreneur, Dr. Bhupendra Kumar Modi, Spice Global has expanded its footprint across Los Angeles, San Francisco, New York, London, New Delhi, Bombay, Dubai, Kuala Lumpur in addition to China and Africa.
For further information regarding Smart Global, please contact Arem Mukim, Manager Brand & Communications:Arem.mukim@spiceglobal.com

Tuesday, February 18, 2014

STEMEDICA ISSUED U.S. PATENT METHOD FOR IDENTIFYING NEURIPOTENT CELLS

(Source: Feburary 18; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced today that the Company has been issued Patent No. US 8,642,286 B2 entitled, Methods for Identifying Neuripotent Cells by the United States Patent and Trademark Office.
The Stemedica patent broadly covers a method for identifying the potency of a cell population, as it becomes neural cells, to engraft in the developing brain of a chick embryo. “This test contributes significantly to the screening of cells capable of engrafting and differentiating in vivo saving both time and valuable resources,” said Alex Kharazi, MD, PhD, Chief Technology Officer at Stemedica. “It is a simple, cost-effective test of neural stem cell potency using a chicken embryonic brain, and is an important and effective step forward in the evaluation and testing of neuripotent cells.”
The chick embryo brain approximates an adult brain. The patented transplant method distinguishes neuripotent stem cells from those which fail to engraft and differentiate into neurons. The method is used for identifying chemical and genetic factors in the manufacture of efficacious neural stem cells.
“In vitro propagated neural stem cells have shown great promise in treating neurodegenerative diseases due to their migratory ability and their multipotency, that is, their ability to differentiate into neural and glial cell lineages,” noted Maynard Howe, PhD, CEO of Stemedica. “Unfortunately, these important features are often lost during tissue culture and expansion and therefore it is critically important to ascertain that expanded neural stem cells retain their potency”.
The method is used to screen candidate neuripotent cells lines for master banking; validation of working cells banks; and, identifying agents and conditions capable of inducing neural differentiation in a cell population.
The patented method was reported in the Journal of Neurosurgery, March 1, 2013 (DOI: 10.3171/2013.1.JNS12698) entitled,“Chicken embryonic brain: an in vivo model for verifying neural stem cell potency” (Kharazi, Alex., et al.). The main objective of the study was to determine whether the in vitro multi-lineage differentiation of human neural stem cells would correlate with their ability to engraft in the developing brain.
“This method gives the biomedical and drug discovery industries the opportunity to significantly reduce animal testing of biologics and drugs. In particular, Stemedica can evaluate the potency of stem cells in vivo in the cleanroom and laboratory setting thus eliminating the requirement of animal testing at outside facilities,” noted Nikolai Tankovich, MD, PhD, FASLMS, President and Chief Medical Officer of Stemedica. “The method supports Stemedica‘s development of cells and cell products for the treatment of neural degenerative and traumatic disorders of the central nervous system.”
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.
Media Contact for Stemedica: Dave McGuigan at dmcguigan@stemedica.com